학술논문
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
Document Type
article
Author
Joaquín Martínez-López; Javier De la Cruz; Rodrigo Gil-Manso; Adrián Alegre; Javier Ortiz; Pilar Llamas; Yolanda Martínez; José-Ángel Hernández-Rivas; Isabel González-Gascón; Celina Benavente; Pablo Estival Monteliu; Víctor Jiménez-Yuste; Miguel Canales; Mariana Bastos; Mi Kwon; Susana Valenciano; Marta Callejas-Charavia; Javier López-Jiménez; Pilar Herrera; Rafael Duarte; Lucía Núñez Martín-Buitrago; Pedro Sanchez Godoy; Cristina Jacome Yerovi; Pilar Martínez-Barranco; María García Roa; Cristian Escolano Escobar; Arturo Matilla; Belén Rosado Sierra; María Concepción Aláez-Usón; Keina Quiroz-Cervantes; Carmen Martínez-Chamorro; Jaime Pérez-Oteyza; Rafael Martos-Martinez; Regina Herráez; Clara González-Santillana; Juan Francisco Del Campo; Arancha Alonso; Adolfo de la Fuente; Adriana Pascual; Rosalía Bustelos-Rodriguez; Ana Sebrango; Elena Ruiz; Eriel Alexis Marcheco-Pupo; Carlos Grande; Ángel Cedillo; Carlos Lumbreras; Andrés Arroyo Barea; José Manuel Casas-Rojo; Maria Calbacho; José Luis Diez-Martín; Julio García-Suárez
Source
Cancers, Vol 15, Iss 5, p 1497 (2023)
Subject
Language
English
ISSN
2072-6694
Abstract
Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February–June 2020; n = 769 (66%)) and later (July 2020–February 2021; n = 397 (34%)) cohorts. Propensity-score matched non-cancer patients were identified from the SEMI-COVID registry. A lower proportion of patients were hospitalized in the later waves (54.2%) compared to the earlier (88.6%), OR 0.15, 95%CI 0.11–0.20. The proportion of hospitalized patients admitted to the ICU was higher in the later cohort (103/215, 47.9%) compared with the early cohort (170/681, 25.0%, 2.77; 2.01–3.82). The reduced 30-day mortality between early and later cohorts of non-cancer inpatients (29.6% vs. 12.6%, OR 0.34; 0.22–0.53) was not paralleled in inpatients with hematologic malignancies (32.3% vs. 34.8%, OR 1.12; 0.81–1.5). Among evaluable patients, 27.3% had post COVID-19 condition. These findings will help inform evidence-based preventive and therapeutic strategies for patients with hematologic malignancies and COVID-19 diagnosis.